PMLiVEGilead adds to CAR-T assets with Cell Design Labs buyoutPMLiVEGilead Sciences Just a few months after shelling out $12bn to buy CAR-T specialist Kite Pharma, Gilead Sciences is boosting its position in the category with a $567m swoop on Cell Desi… Continue reading
News-Medical.net |
St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease
News-Medical.net Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from the … |
STAT |
Bluebird’s gene therapy shows strong results in two blood disorders in small trials
STAT TLANTA — Bluebird Bio (BLUE 1) only discloses gene therapy data on its inherited blood disorder programs twice each year, so expectations — and risks — run high each time the biotech reveals its cards. On Sunday night at the American Society of … bluebird bio Announces Updated Clinical Results from Ongoing …Digital Journal |
Engadget |
Gene therapy gives ‘bubble babies’ immune systems
Engadget Initial results from a new gene therapy technique suggest it could open the doors to a cure for “bubble baby” disease. Lacking the ability to ward off even the most common infections, infants born with the genetic disorder — known as severe combined … |
Genetic Literacy Project |
Fighting infectious diseases with immunotherapy on ‘cusp of commercialization’
Genetic Literacy Project Pharmaceutical firms have invested billions of dollars in cancer immunotherapies over the last few years, and the US Food and Drug Administration (FDA) began approving such therapies in recent months. But the investment bonanza has yet to hit antiviral … |